Search
Dynavax Technologies Corp
DVAXAdd to Watchlist
15.500USD
0.0000.00%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
1.76BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-02-09The current earnings forecast score of Dynavax Technologies Corp is 7.33, ranking 293 out of 391 in the Biotechnology & Medical Research industry. The average price target is 20.50, with a high of 31.00 and a low of 11.00.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
16.000
Target Price
+3.23%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Dynavax Technologies Corp
DVAX
1
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Dynavax Technologies Corp's expected revenue for the next quarter?
Dynavax Technologies Corp's expected revenue is 82.09M.
What is Dynavax Technologies Corp's price target?
Analysts forecast that Dynavax Technologies Corp's price target is USD 20.50, with the highest forecast at USD 31.00 and the lowest forecast at USD 11.00.
How have Dynavax Technologies CorpDVAX's recent earnings per share performed?
The market expectation was USD 0.23, while Dynavax Technologies CorpDVAX's earnings per share (EPS) for the previous quarter was USD 0.16. EPS for the next quarter is expected at USD 0.08.
What is the analyst rating for Dynavax Technologies Corp?
Based on the ratings of Dynavax Technologies Corp's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.